Drugs / ProAgio
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06867822 | Jul 2025 → Jul 2027 expected | colorectal cancer | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 1 | NCT06182072 | Sep 2023 → Jun 2027 expected | pancreatic ductal adenocarcinoma | ProDa BioTech, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05085548 | Oct 2021 → Apr 2025 | malignant exocrine pancreas neoplasm | ProDa BioTech, LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06460298 | Aug 2024 → Jul 2026 overdue | triple-negative breast carcinoma | ProDa BioTech, LLC | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ProAgio | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06460298 ↗ |
| Action | Deplete | “ProAgio potentiated the growth inhibitory effects of GPH in PDX and orthotopic models by depleting integrin β3 expressing cells, leading to ECM remodeling” PMID 41648362 ↗ Jan 2026 |
| Modality | Other / unclassified | “ProAgio is a novel cytotoxin that targets integrin αvβ3-expressing cells.” PMID 41648362 ↗ Jan 2026 |
| Route | Intravenous | “ProAgio is administered to study participants by intravenous injections once every 14 days.” NCT05085548 ↗ |